Duopharma invests US$250,000 in Naluri to boost digital health growth
24 Apr 2020
Leading Malaysian pharmaceutical company, Duopharma Biotech Bhd has agreed to invest US$250,000 (US$1=RM4.36) in Naluri Hidup Sdn Bhd (Naluri) to spur Malaysia’s digital health growth.
Duopharma Biotech said Naluri, a local pioneer in digital therapeutics, has developed a proprietary application platform called “Naluri App”.
“The “Naluri App” is a digital health platform, which combines behavioural science, data science, as well as digital design, to offer a holistic health management programme for users,” Duopharma Biotech said in a joint statement today.
“The programme is targeted to improve the health of those with risks of chronic conditions such as diabetes, heart diseases, cancer and mental health.
“A key feature of Naluri App is multi-disciplinary professional health coaching by qualified psychologists, dietitians, doctors, pharmacists, fitness coaches and other advisers to provide tailored and personalised coaching in a scalable way through instant messaging,” it added.
The professional health coaching is supplemented by digital features including an Artificial Intelligence-powered food journal, a thought journal, a health curriculum of daily modules, and a planner that includes reminders and tracking for medication adherence.
Duopharma Biotech is confident that Naluri’s concept and platform will be seamlessly integrated into its Specialty and Consumer Healthcare businesses and help to offer premium health packages for its customers.
Commenting on this new initiative, Duopharma Biotech group managing director Leonard Ariff Abdul Shatar said one of the Group’s primary strategies is the innovative use of emerging technologies to provide smarter solutions for a healthier life for all.
“As encouraged by the Government, I am heartened to see many instances in our nation of a more collaborative approach, which is fundamental to better empower us all to overcome current challenges,” he said.
Meanwhile, Naluri chief executive officer Azran Osman Rani said the strategic partnership has enabled Naluri to enhance its capabilities to serve specific chronic disease therapeutic areas to build an evidence-based of repeatable health improvements.
Duopharma Biotech’s investment in Naluri is via a Simple Agreement for Future Equity, which brings the latter’s total funding to over US$3 million to date.
Posted on : 24 April 2020